The global mice model generation market size was estimated at USD 1.35 billion in 2025 and is projected to hit around USD 3.05 billion by 2035, growing at a CAGR of 8.5% during the forecast period from 2026 to 2035.
The mice model generation market plays a critical role in biomedical research, drug development, and disease modeling. Mouse models are widely used due to their genetic similarity to humans, short reproductive cycles, and ease of genetic manipulation. These models enable researchers to study disease mechanisms, evaluate drug efficacy, and assess safety before clinical trials.
Technological advancements have significantly transformed the market, particularly with the introduction of gene-editing tools such as CRISPR-Cas9. These technologies allow precise and rapid modification of the mouse genome, enabling the creation of customized models that mimic human diseases. This has revolutionized research in areas such as oncology, neurology, immunology, and rare genetic disorders.
The market is driven by increasing investment in life sciences research, rising demand for personalized medicine, and the growing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular conditions. Pharmaceutical and biotechnology companies rely heavily on mouse models to validate drug targets and conduct preclinical testing.
Additionally, academic and research institutions continue to play a vital role in advancing mouse model technologies. Collaborative efforts between academia and industry are fostering innovation and accelerating the development of new models. The outsourcing of model generation to specialized service providers and CROs is also gaining momentum, as it allows organizations to reduce costs and focus on core research activities.
AI and ML are revolutionizing the mice model generation industry by accelerating the design and production of genetically engineered models, primarily through enhanced CRISPR-Cas9 technologies. These technologies allow researchers to analyse vast genomic datasets to design optimal guide RNAs, reducing off-target effects and increasing precision in creating disease-specific models, particularly in oncology. ML algorithms are enhancing the development of humanized mouse models by predicting species-agnostic antibody response, thus creating more reliable preclinical tools for translational research.
| Report Coverage | Details |
| Market Size in 2026 | USD 1.46 Billion |
| Market Size by 2035 | USD 3.05 Billion |
| Growth Rate From 2026 to 2035 | CAGR of 7.5% |
| Base Year | 2025 |
| Forecast Period | 2026 to 2035 |
| Segments Covered | By Technology, By End-user, By Geography |
| Market Analysis (Terms Used) | Value (USD Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Biocytogen, Charles River Laboratories, Cyagen Biosciences, Gempharmatech, genOway |
Market Driver
Increasing Demand for Preclinical Research and Drug Development
The primary driver of the mice model generation market is the growing demand for preclinical research in drug development. Before any drug reaches clinical trials, it must undergo extensive testing to evaluate its safety, efficacy, and potential side effects. Mouse models are an essential component of this process, as they provide valuable insights into disease mechanisms and therapeutic responses.
The rising prevalence of chronic and complex diseases such as cancer, Alzheimer’s disease, and autoimmune disorders has intensified the need for advanced research models. For example, genetically engineered mouse models (GEMMs) are widely used in oncology research to study tumor progression and evaluate targeted therapies. Similarly, mouse models are used to study neurodegenerative diseases by replicating specific genetic mutations associated with these conditions.
Pharmaceutical and biotechnology companies are investing heavily in R&D to develop innovative therapies, including biologics, gene therapies, and cell-based treatments. These therapies require highly specialized mouse models that accurately mimic human biology. The ability of CRISPR technology to rapidly generate such models has further accelerated market growth.
Additionally, regulatory requirements mandate thorough preclinical testing, reinforcing the importance of mouse models in drug development. As the pipeline of new drugs continues to expand, the demand for mice model generation is expected to grow significantly.
Market Restraint
Ethical Concerns and Regulatory Restrictions on Animal Testing
One of the major restraints in the mice model generation market is the ethical concerns associated with animal testing. The use of animals in research has been a subject of debate, with increasing pressure from animal welfare organizations and regulatory bodies to reduce or eliminate animal usage.
Governments and regulatory agencies have implemented strict guidelines to ensure ethical treatment of laboratory animals. Researchers are required to follow the principles of the 3Rs—Replacement, Reduction, and Refinement—which aim to minimize animal usage and improve welfare conditions. Compliance with these regulations can increase operational complexity and costs for organizations involved in mouse model generation.
Furthermore, advancements in alternative research methods, such as organ-on-chip technologies and in vitro cell models, are gaining attention as potential substitutes for animal testing. While these methods cannot fully replicate the complexity of living organisms, they are being increasingly used for preliminary studies.
Public perception and ethical considerations may also impact funding and investment in animal-based research. As a result, companies and research institutions must balance the need for accurate preclinical models with ethical responsibilities, which can pose challenges for market growth.
Market Opportunity
Advancements in Gene Editing and Personalized Medicine
The rapid advancement of gene-editing technologies presents a significant opportunity for the mice model generation market. CRISPR-Cas9 and other genome-editing tools have revolutionized the ability to create precise and customized mouse models, enabling researchers to study complex genetic conditions and develop targeted therapies.
Personalized medicine, which focuses on tailoring treatments to individual patients based on their genetic profiles, is driving demand for specialized mouse models. For example, patient-derived xenograft (PDX) models involve implanting human tumor tissues into mice, allowing researchers to study tumor behavior and test personalized treatment options.
Additionally, advancements in large DNA insertions and multi-gene editing are enabling the development of models that closely mimic human diseases. These innovations are particularly valuable in studying rare genetic disorders, where traditional models may not be sufficient.
The growing interest in gene therapies and precision medicine is expected to create new opportunities for mouse model generation companies. By providing highly customized and accurate models, these companies can support the development of next-generation therapies and expand their market presence.
How did the CRISPR Knockout segment dominate the Mice Model Generation market?
The CRISPR Knockout segment is driven by accelerating mouse model development from nearly a year to just three months, enabling immediate phenotypic observation in the first generation. Its unique multiplexing capability allows for the simultaneous modification of multiple genes, which is essential for decoding the genetic complexities of diseases like cancer and diabetes. The technological advancements have established CRISPR as the dominant, high-performance engine driving precision drug discovery and genetic research.
How did the CRISPR Knockin segment expect to hold the fastest-growing Mice Model Generation market in the coming years?
The CRISPR Knockin segment is driven by its ability to precisely integrate human genes, which has made it indispensable for creating humanized mice, which are critical for accurate results in oncology and immunology research. The rapid adoption by biotechnology firms seeking to accelerate drug validation pipelines is cementing its role as the future of precision genomic medicine.
How did the pharmaceutical companies segment account for the largest share in the Mice Model Generation market?
The pharmaceutical companies segment is driven by slashing mouse model development time from nearly a year to just three months, allowing for immediate phenotypic observation. Its high-throughput capability, enhanced by methods such as Zygote Electroporation, enables the simultaneous targeting of multiple genes with unprecedented precision and animal costs. Its combination of speed, simplicity, and cost-effectiveness has established it as the indispensable gold standard for modern genetic research.
How did the academic and research facilities segment expect to hold the fastest-growing Mice Model Generation market in the coming years?
The academic and research facility segment is driven by a surge in government and private funding dedicated to developing humanized models for Alzheimer’s, cancer, and rare diseases. The widespread adoption of CRISPR/Cas9 technology within these institutions has drastically reduced the time and cost required to engineer complex genetic constructs. By strengthening their internal transgenic core facilities, universities can now pilot specialized strains that offer superior translation to human clinical outcomes.
North America dominates the mice model generation market, due to strong investment in biomedical research and the presence of leading pharmaceutical and biotechnology companies. The region benefits from advanced research infrastructure, favorable funding environment, and high adoption of innovative technologies. Additionally, collaborations between academic institutions and industry players are driving innovation and market growth.
Asia Pacific is the fastest-growing region, driven by expanding biotech industries and increasing investment in research and development. Countries such as China, Japan, and India are emerging as key players in the global market. Lower operational costs and supportive government initiatives are attracting international companies to establish research facilities in the region. The growing focus on healthcare innovation and drug development is further contributing to market expansion.
Biocytogen is a global leader in providing humanized mouse models, specifically utilizing their proprietary SUPCE™ technology to create large-fragment in situ gene replacements for drug target validation.
As a premier global supplier, Charles River offers an extensive portfolio of standard, inbred, outbred, and highly specialized genetically engineered mouse and rat models, such as immunodeficient and humanized strains.
Cyagen Biosciences has established itself as a leading provider of custom, genetically modified mouse models, including its proprietary TurboKnockout® technology, which combines the precision of ESCs with the speed of CRISPR/Cas9 for accelerated model generation.
Gempharmatech specializes in building comprehensive, high-quality genetically engineered mouse models (GEMMs), most notably through their "Knockout All Project" (KOAP), which aims to create knockout or conditional knockout strains for nearly all protein-coding genes.
genOway, a leader in CRISPR/Cas9 technologies, focuses on creating, validating, and marketing highly customized transgenic, knockout, and knock-in mice for both academic and commercial clients.
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2035. For this study, Nova one advisor, Inc. has segmented the global Mice Model Generation market
By Technology
By End-user
By Geography
North America
Europe
Asia Pacific
Latin America
Middle East & Africa (MEA)
Mice Model Generation Market
Download Sample
Request Customization
Request Customization
Download Sample